STATEMENT OF NEED
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kidney damage. MM is primarily considered a disease of older adults, with a median age at diagnosis of 69 years. From 1975 to 2007, the incidence increased by 11.4%, and is expected to continue to rise in conjunction with the aging population. Early diagnosis is difficult because symptoms often do not appear until the malignancy is in advanced stages. The 5-year survival rate remains only 52.2%.
Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with MM.
Upon completion of this activity, participants should be able to:
Learning objectives apply to all professions in the target audience. There are no prerequisites for this activity.
Beth Faiman, PhD, MSN, APN-BC, AOCN® (Chairperson)
Nurse Practitioner, Department of Hematologic Oncology
Cleveland Clinic Taussig Cancer Institute
Charise Gleason, MSN, NP-C, AOCNP®
Advanced Practice Provider Chief
Winship Cancer Institute of Emory University
Donna D. Catamero, ANP-BC, OCN®, CCRC
Associate Director, Myeloma Translation Research
The Mount Sinai Health System
Tiffany Richards, PhD, ANP-BC
Advanced Practice Nurse
MD Anderson Cancer Center
There is no fee to participate in or claim NCPD credit for this activity.
Please note that USF Health and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
Nursing Continuing Professional Development
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization.
USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.
Planning Committee, USF Health OCPD staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of South Florida, Office of Continuing Professional Development.
Relevant financial relationships exist between the following individuals and commercial interests:
Beth Faiman, PhD, MSN, APN-BC, AOCN®, discloses that she has served as a consultant for Bristol Myers Squibb, Janssen, and Sanofi.
Tiffany Richards, PhD, ANP-BC, discloses that she has served as a consultant or on an advisory board/panel for Bristol Myers Suibb, GlaxoSmithKline, Janssen, Legend, Sanofi, and Takeda.
Charise Gleason, MSN, NP-C, AOCNP®, discloses that she has served as a consultant for Pfizer.
Donna D. Catamero, ANP-BC, OCN®, CCRC, discloses that she has served as a consultant or on an advisory board/panel for Bristol Myers Squibb.
REQUIREMENTS FOR CREDIT
Participants must sign-in before the start of the activity to verify attendance. All participants are asked to complete a pretest and a posttest for outcomes assessment; a passing score is not required. At the conclusion of the activity participants must complete an evaluation, attesting to the time spent in this live activity, claiming credit. Certificates of Completion will be emailed within two weeks of the activity.
UNAPPROVED USE DISCLOSURE
USF Health and i3 Health require NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants from Celgene Corporation, Sanofi Genzyme, and Karyopharm Therapeutics. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
AMERICANS WITH DISABILITIES ACT